NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,145.20
- Market cap
- ₹51,899 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.0×Sector 42.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Other results update announcements
All →Sai Life Science Results Update
Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.
Lead Reclaim and Rubber Products Results Update
Lead Reclaim and Rubber Products reported H1 FY27 revenue of Rs.3,612 lakhs, up 64.93%, and PAT of Rs.320 lakhs, up 223%. The press release shows P&L highlights and the company announced an earnings call on November 6, 2026.
Kratikal Tech Results Update
Kratikal Tech's H1 FY27 revenue rose 65% to ₹22.32 Cr; PAT rose 130% to ₹2.80 Cr. Order book stood at ₹42.6 Cr.
Euro Pratik Sales Results Update
Euro Pratik's Q2 FY27 revenue rose 20% year-on-year to ₹115.7 Crore, with PAT up 15%. The release also highlights the Drashti Surfaces acquisition.
Kalyani Forge Results Update
Kalyani Forge's board approved an indicative ₹45 crore FY27 funding plan and reported H1 FY27 PBT up 118.8%. Q2 revenue fell 2.2%, but EBITDA margin widened.
Cello World Results Update
Cello World's Q2 FY27 revenue rose 7.8% to Rs.633 crore, while PAT fell 10.3%. This investor press release highlights results, not the full statement.